Our study provides novel evidence that ADO pathway is induced after RFA therapy, and its inhibition during combination therapy impairs tumor enlargement and improves anti-tumor immunity in a preclinical model of PDA. This evidence concerns the gene ADO and Patent ductus arteriosus.